Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NM21-1480 |
Synonyms | |
Therapy Description |
NM21-1480 is a recombinant, trispecific monovalent antibody-based molecule that targets PD-L1, 4-1BB, and human serum albumin, potentially resulting in activation of T cell immune responses and enhanced T cell-mediated cytotoxicity, leading to inhibition of tumor cell proliferation (NCI Drug Dictionary, Cancer Research 80(16), Abstr 2276). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NM21-1480 | NM21 1480|NM211480|ND 021|ND-021|ND021 | NM21-1480 is a recombinant, trispecific monovalent antibody-based molecule that targets PD-L1, 4-1BB, and human serum albumin, potentially resulting in activation of T cell immune responses and enhanced T cell-mediated cytotoxicity, leading to inhibition of tumor cell proliferation (NCI Drug Dictionary, Cancer Research 80(16), Abstr 2276). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04442126 | Phase Ib/II | NM21-1480 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Terminated | USA | ESP | 1 |